Moderna, Inc. - Common Stock (MRNA)
26.85
-0.64 (-2.33%)
NASDAQ · Last Trade: Oct 22nd, 8:18 PM EDT
Washington D.C., October 22, 2025 – The world stands at a critical juncture as the 2025 Economic Freedom of the World index, prominently released by the Fraser Institute in collaboration with the Cato Institute, reveals an alarming and unprecedented trend: a decline in global economic freedom for four consecutive years.
Via MarketMinute · October 22, 2025
Discover the top S&P500 movers in Wednesday's after-hours session and stay informed about the post-market dynamics.
Via Chartmill · October 22, 2025
The biotech's innovative qualities will come in handy.
Via The Motley Fool · October 22, 2025
Shares could keep sliding, as Moderna's post-COVID pipeline has yet to reach a breakthrough.
Via The Motley Fool · October 22, 2025
DataVault AI and Wellgistics Health are collaborating to bring blockchain technology to the US prescription drug market.
Via Benzinga · October 22, 2025
Don't try to catch a falling surgical knife.
Via The Motley Fool · October 21, 2025
U.S. stocks rise on Monday, with the Dow up 500+ points. Moderna and Cleveland-Cliffs report gains. Most S&P sectors close higher, with Fear & Greed Index at 30.3.
Via Benzinga · October 21, 2025
Via Benzinga · October 20, 2025
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday.
Via Chartmill · October 20, 2025
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.
Via Chartmill · October 20, 2025
U.S. stock futures rose on Monday following Friday’s advances. Futures of major benchmark indices were higher.
Via Benzinga · October 20, 2025
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets.
But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
Via StockStory · October 20, 2025
The biotechnology sector is currently experiencing a significant surge in investor attention, characterized by a blend of cautious optimism and strategic focus. As of October 2025, this heightened interest is not merely an isolated phenomenon but rather a potent indicator of broader market movements, significantly impacting stock futures and the
Via MarketMinute · October 19, 2025
The healthcare industry is experiencing a profound transformation, propelled by the accelerating adoption of artificial intelligence. While AI's potential has long been discussed, recent advancements in generative AI are now yielding tangible benefits, delivering measurable returns across clinical and administrative domains. This shift is further amplified by the emerging paradigm of 'agentic AI,' which promises [...]
Via TokenRing AI · October 17, 2025
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday.
Via Chartmill · October 17, 2025
Moderna's sales have plummeted in recent years along with diminishing demand for COVID vaccines.
Via The Motley Fool · October 15, 2025
Let's delve into the developments on the US markets one hour before the close of the markets on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Via Chartmill · October 15, 2025
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session.
Via Chartmill · October 15, 2025
The United States government is currently in the throes of its third week of a shutdown, a fiscal impasse that commenced on October 1, 2025, following a congressional failure to enact appropriations legislation for the 2026 fiscal year. This eleventh government shutdown in U.S. history is sending ripples of
Via MarketMinute · October 14, 2025
Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least $5 billion.
Via Benzinga · October 14, 2025
Whether you're well steeped in Foolishness or at the beginning stages of your investing journey, these are nine foundational truths not to be forgotten.
Via The Motley Fool · October 14, 2025
Shares of biotechnology company Moderna (NASDAQ:MRNA)
jumped in the afternoon session after the company presented promising early data for its investigational cancer antigen therapy, mRNA-4359, from a Phase I/II study.
Via StockStory · October 13, 2025
Moderna's Phase 1/2 study shows mRNA-4359 plus pembrolizumab yields 24% response rate and 60% disease control in resistant melanoma patients.
Via Benzinga · October 13, 2025
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding.
Without a clear path to profitability, these businesses risk dilution, mounting debt, or even bankruptcy.
Via StockStory · October 13, 2025